Fitzpatrick, Cella, Harper & Scinto

Fitzpatrick, Cella, Harper & Scinto was a premier intellectual property law firm that specialized in the pharmaceutical, biotechnology, and life sciences sectors. Headquartered in New York, the firm was widely recognized for its expertise in complex patent litigation, including high-stakes Hatch-Waxman and biologics cases. They provided a full range of IP services, including patent prosecution, licensing, and enforcement for many of the world's leading healthcare companies. In November 2018, the firm merged with Venable LLP, a move that integrated its elite IP practice into Venable's broader national platform. The legacy of the firm continues through Venable's expanded life sciences and intellectual property litigation groups.